J&J's apalutamide meets in Phase III for non-metastatic CRPC

Newly released data showed apalutamide (JNJ56021927) from Johnson & Johnson (NYSE:JNJ) met the primary endpoint in the Phase III SPARTAN trial to treat non-metastatic castration-resistant prostate cancer. The data were released in an abstract ahead of this week's American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.

On the 1,207-patient trial's primary endpoint, once-daily 240 mg oral apalutamide plus androgen deprivation therapy (ADT) significantly improved metastasis-free survival (MFS) vs. placebo plus ADT (40.5 vs. 16.2 months, HR=0.28, 95% CI: 0.23, 0.35, p<0.0001). Apalutamide plus ADT also met the secondary endpoints of improving time to metastasis, progression-free survival (PFS) and time to symptomatic progression vs. placebo plus ADT...